MK-0431: Agent for type 2 diabetes dipeptidyl-peptidase IV (CD26) inhibitor

Drugs of the Future

Volumn 30, Issue 4, 2005, Pages 337-343

  Sorbera, L A ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BENZENE DERIVATIVE; BETA AMINO ACID; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FLUORINE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 [9-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; INSULIN; PYRAZINE DERIVATIVE; SERINE PROTEINASE; SITAGLIPTIN; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; APPETITE; AREA UNDER THE CURVE; CLINICAL TRIAL; DIET; DOG; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; HALF LIFE TIME; HORMONAL REGULATION; HUMAN; HYDROLYSIS; INSULIN RELEASE; MONKEY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; RAT; REVIEW; STOMACH EMPTYING;

EID: 21744439668     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2005.030.04.898484     Document Type: Review

References (24)

1. Kim, D., Wang, L., Beconi, M. et al. (2R)-4-Oxo-4-[3-(trifluoromethyl)-5, 6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl) butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005, 48: 141-51.
2. Edmondson, S.D., Fisher, M.H., Kim, D., MacCoss, M., Parmee, E.R., Weber, A.E., Xu, J. (Merck & Co., Inc.). β-Amino tetrahydroimidazo[1,2-a] pyrazines and tetrahydrotrioazole[4,3-a]pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes. EP 1412357, JP 2004536115, US 2003100563, US 6699871, WO 0304498.
3. Dreher, S.D., Ikemoto, N., Njolito, E., Rivera, N.R., Tellers, D.M., Xiao, Y. (Merck & Co., Inc.). Process to chiral β-amino acid derivatives. WO 0485661.
4. Xiao, Y., Armstrong, J.D. III, Krska, S.W., Njolito, E., Rivera, N.R., Sun, Y., Rosner, T. (Merck & Co., Inc.). Process for the preparation of chiral beta amino acid derivatives by asymmetric hydrogenation. WO 0485378.
5. Cypes, S.H., Chen, A.M., Ferlita, R.R., Hansen, K., Lee, I., Vydra, V.K., Wenslow, R.M. Jr. (Merck & Co., Inc.). Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor. US 2005032804, WO 0503135.
6. Angelaud, R., Armstrong, J.D. III, Askin, D., Balsells, J., Hansen, K., Lee, J., Maligres, P.E., Rivera, N.R., Xiao, Y., Zhong, Y.-L. (Merck & Co., Inc.). Process and intermediates for the preparation of beta-amino acid amide dipeptidyl peptidase-IV inhibitors. WO 0487650.
7. Prous Science Drug R&D Backgrounders: Diabetes (online publication). Updated April 28, 2005.
8. Saltiel, A.R. Series introduction: The molecular and physiological basis of insulin resistance: Emerging implications for metabolic and cardiovascular diseases. J Clin Invest 2000, 106: 163-4.
9. Narayan, K.M., Boyle, J.P., Thompson, T.J., Sorensen, S.W., Williamson, D.F. Lifetime risk for diabetes mellitus in the United States. JAMA - J Am Med Assoc 2003, 290: 1884-90.
10. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004, 27: S5-10.
11. Ruilope, L.M. Recent developments in the treatment of type 2 diabetes mellitus. Cardiovasc Drugs Ther 2003, 17: 151-8.
12. Orskov, C. Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia 1992, 35: 701-11.
13. Zander, M., Madsbad, S., Madsen, J.L., Holst, J.J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: A parallel-group study. Lancet 2002, 359: 824-30.
14. Deacon, C.F., Holst, J.J., Carr, R.D. Glucagon-like peptide-1: A basis for new approaches to the management of diabetes. Drugs Today 1999, 35: 159-70.
15. Perfetti, R., Hui, H. The role of GLP-1 in the life and death of pancreatic beta cells. Horm Metab Res 2004, 36: 804-10.
16. Holz, G.G., Chepurny, O.G. Glucagon-like peptide-1 synthetic analogs: New therapeutic agents for use in the treatment of diabetes mellitus. Curr Med Chem 2003, 10: 2471-8.
17. Wiedeman, P.E., Trevillyan, J.M. Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes. Curr Opin Investig Drugs 2003, 4: 412-20.
18. Ahren, B., Schmitz, O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 2004, 36: 867-76.
19. Kim, D., Wang, L., Kowalchick, J. et al. MK-0431: A potent, orally active DP-IV inhibitor for the treatment of type 2 diabetes. 228th ACS Natl Meet (Aug 22-26, Philadelphia) 2004, Abst MEDI 208.
20. Thornberry, N.A., Eiermann, G., Kim, D. et al. Dipeptidyl peptidase IV (DP-IV) inhibition for the treatment of type 2 diabetes: Potential importance of selective inhibition and discovery of MK-0431. 40th Annu Meet Eur Assoc Study Diabetes (Sept 5-9, Munich) 2004, Abst 113.
21. Weber, A.E., Kim, D., Beconi, M. et al. MK-0431 is a potent, selective, dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. 64th Annu Meet Sci Sess Am Diabetes Assoc (June 4-8, Orlando) 2004, Abst 633-P.
22. Herman, G.A., Zhao, P.-L., Dietrich, B. et al. The DP-IV inhibitor MK-0431 enhances active GLP-1 and reduces glucose following an OGTT in type 2 diabetics. 64th Annu Meet Sci Sess Am Diabetes Assoc (June 4-8, Orlando) 2004, Abst 353-OR.
23. Merck 2004 Annual Business Briefing. Merck & Co., Inc. Web Site December 14, 2004.
24. Ono and Merck in product licensing arrangements. Ono Pharmaceutical Press Release Nov 10, 2004.